stockportfolio.pro
Summit Therapeutics Inc. (SMMT)
Healthcare · Biotechnology · NasdaqGM
Summit Therapeutics Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $57.09M | $860,000 | $1.81M | $705,000 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $10.87M | $-52.70M | $-88.60M | $-78.78M | $-614.93M | $-221.31M | $-1.08B |
| Net margin | 19.0% | -6127.6% | -4897.8% | -11174.8% | — | — | — |
Source: Summit Therapeutics Inc. SEC filings (10-K).
Explore 7 years of Summit Therapeutics Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SMMT in your portfolio →
Summit Therapeutics Inc. financial history by metric
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Summit Therapeutics Inc. — frequently asked questions
What is Summit Therapeutics Inc.'s revenue?
Summit Therapeutics Inc. (SMMT) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Summit Therapeutics Inc. profitable?
No — SMMT reported a net loss of $-1.08B in fiscal 2025.
What is SMMT's P/E ratio?
Summit Therapeutics Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Summit Therapeutics Inc. have?
As of fiscal year 2025, SMMT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Summit Therapeutics Inc.'s market cap?
Summit Therapeutics Inc. (SMMT) has a market capitalization of about $10.35B, based on the latest data in our nightly-refreshed cache.
When does Summit Therapeutics Inc.'s fiscal year end?
SMMT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Summit Therapeutics Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.